WAVEMAN · COMPANY

YSG · Yatsen Holding Ltd

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

YSG

Name: Yatsen Holding Ltd (YSG) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Yatsen Holding Ltd

PHARMA & BIOTECH · PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS · CIK 0001819580

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+32.2%

XBRL, annual

NET MARGIN

-1.9%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

15 funds added or opened last quarter

below 74% of Pharma & Biotech

REVENUE

+32.2% year over year

more than 74% of Pharma & Biotech

MARGIN

-1.9% net margin

more than 64% of Pharma & Biotech

BUYBACKS

$15.9M repurchased, FY to 2025-12-31

below 64% of Pharma & Biotech

SHORT

no short interest reported

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 15 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Yatsen Holding Ltd in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

HHLR ADVISORS, LTD.

4,885,873.0 sh

$15.5M

MORGAN STANLEY

2,766,425.0 sh

$8.8M

BANK OF AMERICA CORP /DE/

1,545,081.0 sh

$4.9M

Yiheng Capital Management, L.P.

946,193.0 sh

$3.0M

RENAISSANCE TECHNOLOGIES LLC

541,047.0 sh

$1.7M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco Golden Dragon China ETF

$149.9K POSITION · AS OF 2026-04-30

0.1%

State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF

$106.1K POSITION · AS OF 2026-03-31

0.0%

ActivePassive International Equity ETF

$59.0K POSITION · AS OF 2026-02-28

0.0%

Avantis Emerging Markets Small Cap Equity ETF

$6.2K POSITION · AS OF 2026-02-28

0.0%

Emerging Markets Sustainability Core 1 Portfolio

$72.8K POSITION · AS OF 2026-04-30

0.0%

State Street(R) SPDR(R) S&P(R) China ETF

$19.8K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$4.3B	$3.4B	$3.4B	$3.7B
GROSS PROFIT	$3.4B	$2.6B	$2.5B	$2.5B
OPERATING INCOME	$-185.8M	$-824.9M	$-913.4M	$-928.9M
NET INCOME	$-80.9M	$-708.2M	$-747.8M	$-815.4M
EPS (DILUTED)	-0.04	-0.35	-0.34	-0.34
OPERATING CASH FLOW	$-94.7M	$-243.7M	$-107.4M	$136.2M
CASH	$765.4M	$817.4M	$836.9M	$1.5B
BUYBACKS	$111.0M	$405.8M	$212.7M	$654.6M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE